Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Leukemia. 2021 Mar;35(3):897-900. doi: 10.1038/s41375-020-0961-3. Epub 2020 Jul 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5 / genetics*
  • Humans
  • Lenalidomide / therapeutic use*
  • Mutation*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / pathology
  • Prognosis
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Lenalidomide